Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Apr 2014

Volume: 15

Issue: 4

Affiliations

[1 ] Royal Marsden Hospital, London, UK. Electronic address: ian.judson@icr.ac.uk.

[2 ] Erasmus MC Cancer Institute, Rotterdam, Netherlands.

[3 ] Leiden University Medical Center, Leiden, Netherlands.

[4 ] Eberhard Karls Universitaet Tübingen, Tübingen, Germany; Christian-Albrechts-University, Kiel, Germany; Catholic Hospital, Consortium, Bielefeld, Germany.

[5 ] Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

[6 ] Department of Medicine, NetSARC and LYRIC, Centre Leon Berard, Lyon, France; University Centre Leon Berard, Lyon, France.

[7 ] Netherlands Cancer Institute, Amsterdam, Netherlands.

[8 ] National Cancer Institute, Bratislava, Slovakia.

[9 ] The London Sarcoma Service, University College Hospital, London, UK.

[10 ] Mannheim University Medical Center, Mannheim, Germany.

[11 ] Department of Oncology, Herlev Hospital-University Copenhagen, Herlev, Denmark.

[12 ] Department of Oncology, McGill University Montreal, QC, Canada; Montreal General Hospital, Montreal, QC, Canada.

[13 ] EORTC, Brussels, Belgium.

[14 ] Royal Marsden Hospital, London, UK.

[15 ] Azienda ULSS 9 Treviso, Treviso, Italy.

[16 ] Department of Medical Oncology, Radboud University Medical Center Nijmegen, Netherlands.

Article

Publisher Item ID: S1470-2045(14)70063-4

DOI: 10.1016/S1470-2045(14)70063-4

PubMed ID: 24618336

SO-VID: b681543e-d207-400d-969d-57d118582964

History

Data availability:

Comments

Comment on this article

scite_

Cited by 393

See all cited by